Formulary Digital Edition February 2010


Approaching the ideal selective estrogen receptor modulator for prevention and treatment of postmenopausal osteoporosis; Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes; and Agents in late-stage development for renal diseases

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.